MOR and COMT SNP Polymorphism and Pain

• Conditions: Pain Relief
• Interventions: Other: SNP genotyping

• Registration Number: NCT00773760
• Lead Sponsor: East Tallinn Central Hospital

Brief Summary

Patients with certain polymorphism in the MOR and COMT genes will display differences in their response to analgesics.

Detailed Description

After tissue injury, there is great interindividual variability among patients in the amount of pain experienced (pain intensity and duration of pain) and in the degree of pain relief from analgesics. In experimental settings, Single Nucleotide Polymorphisms (SNP) at the MOR and COMT genes have been found to alter the response to opioids in in vitro models and in human.We will collect clinical data on one hundred patients undergoing surgery. We will obtain DNA extracted via PCR techniques from the patients' blood and we will identify SNPs at the mu opioid receptor and catechol-O-methyltransferase genes. We will analyze the data to search for correlation between clinical patterns of postoperative pain and opioid effects and SNPs.

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-10-15
• Study First Submitted QC: 2008-10-15
• Study First Posted: 2008-10-16
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-04
• Last Update Posted: 2009-08-06
• Primary Completion: 2009-10
• Study Completion: 2009-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• 18 years of age and older
• Give informed consent to participate in this study

Exclusion Criteria

• Neurologic or psychiatric disease sufficient, in the clinical judgment of the investigator, to compromise informed consent or data collection
• ASA classification score 3 or above
• Patients with past or present history of substance abuse.
• Patients with a history of chronic pain requiring daily analgesic use for more then one month.
• Patients with a current diagnosis of anxiety or depression requiring medical treatment
• Patients allergic to morphine

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
dosing	SNP genotyping	-

Primary Outcome Measures

Name	Time	Method
Postoperative assessments include PCA use (e.g., number of patient demands, total morphine administered) in each 24-h interval during the 48-h study period - primary endpoint.	48 hours

Secondary Outcome Measures

Name	Time	Method
No secondary outcome endpoint	no time frame

Trial Locations

Locations (1)

Yuri Kolesnikov MD PhD; 🇪🇪 Tallinn, Estonia